Aristotle Capital Management, LLC, an investment management company, released its “International Equity Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned ‐7.90% gross of fees, compared to a ‐9.36% return for the MSCI EAFE Index and ‐9.91% return for the MSCI ACWI ex USA Index. Both security selection and sector allocation were responsible for the fund’s outperformance in the quarter relative to the MSCI EAFE Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.
Aristotle Capital highlighted stocks like GSK plc (NYSE:GSK) in its Q3 2022 investor letter. Headquartered in Brentford, the United Kingdom, GSK plc (NYSE:GSK) is a UK-based pharmaceutical company. On November 29, 2022, GSK plc (NYSE:GSK) stock closed at $34.36 per share. One-month return of GSK plc (NYSE:GSK) was 3.74%, and its shares lost 18.41% of their value over the last 52 weeks. GSK plc (NYSE:GSK) has a market capitalization of $69.878 billion.
Aristotle Capital made the following comment about GSK plc (NYSE:GSK) in its Q3 2022 investor letter:
“GSK plc (NYSE:GSK), the U.K.‐headquartered pharmaceutical company, was the largest detractor. GSK completed the demerger of its consumer health business in July, creating the independent, publicly traded company Haleon. As discussed below, we made Haleon a full position following the spinoff. We believe the separation unlocks value and allows remaining GSK to benefit from greater focus on biopharmaceuticals and vaccines. After managing the completed spinoff, CFO Iain Mackay announced his plans to retire in May 2023, to be replaced by Julie Brown. Having served in previous CFO posts at both the luxury goods brand Burberry, as well as the pharmaceutical firm AstraZeneca, we look forward to following Ms. Brown’s initiatives at GSK.
Moreover, the company has been advancing on our catalyst of market share gains for Shingrix, its vaccine to prevent shingles. Shingrix again delivered record sales growth and continues to be a key driver of GSK’s vaccine revenue expansion. Lastly, legal concerns related to potential side effects from the heartburn medicine Zantac made headlines. Although Zantac was marketed by several firms and its associated risks have been known for a number of years, upcoming lawsuits in the U.S. received media attention this quarter. We are closely following the litigation and may have more to share in future commentaries. In the interim, we find the price adjustment to be overdone. The largest side effect‐related drug settlements have been in the single‐digit billions, while more than £20 billion in market capitalization has been removed from GSK. Despite recent share price declines, we remain confident in GSK’s ability to further penetrate markets with its current products and evolve its pipeline of innovative medicines.”
Photo by Steven Cornfield on Unsplash
GSK plc (NYSE:GSK) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held GSK plc (NYSE:GSK) at the end of the third quarter, which was 34 in the previous quarter.
We discussed GSK plc (NYSE:GSK) in another article and shared the list of best biotech stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.
11 Biggest Malls in Europe
10 Best 5% Dividend Stocks To Buy
11 Best Digital Payments Stocks To Buy
Disclosure: None. This article is originally published at Insider Monkey.
Dividend stocks. They’re the very picture of the reliable standby, the sound defensive play that investors make when markets turn south. Div stocks tend not to show as extreme shifts as the broader markets, and they offer a steady income stream no matter where the markets go. And it’s not just retail investors who move into dividend stocks. Recent regulatory filings show that billionaire Steve Cohen has bought big into high-yield dividend stocks. Cohen has built a reputation for success, and his
With U.S. stocks down more than 20% so far this year, investors are looking for some good news – and it may be coming from a prominent Wall Street analyst who says the current bear market could come to an … Continue reading → The post Top Morgan Stanley Strategist Says This Is When the Bear Market ‘Will Be Over Probably' appeared first on SmartAsset Blog.
Yahoo Finance Live examines Boeing shares after United Airlines orders dozens of 787 Dreamliner jets.
Want the recipe for a wildly successful investment? Take a large measure of market leadership, add a smidgen of secular tailwinds, and top it off with a large addressable market.
And if you’re behind? It’s OK boomer. There’s still some time to catch up.
Thanks to a mild obsession with so-called “cash stuffing” — which has racked up more than 700 million views on TikTok — Gen Z has made an old-school money hack a viral sensation. Cash stuffing is a technique that encourages people to pay for things with cash, and as a result, they should end up saving more of their money. If this sounds familiar, that’s because it is: Cash stuffing mimics a strategy used by Dave Ramsey, known as the envelope system.
The Chinese EV maker has surged more than 50% despite an earnings miss and slashed guidance
Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday.
Weaker demand for lumber has weighed on prices, making it one of the biggest commodity price decliners this year. The outlook isn’t good, either.
Wedbush on Friday launched coverage of Green Thumb Industries Inc. , Cresco Labs Inc. , Curaleaf Holdings Inc. and Trulieve Cannabis Corp. with outperform ratings. Analyst Gerald Pascarelli said of the four cannabis companies Green Thumb Industries ranks as Wedbush's top pick. "We believe that brighter days lie ahead for the U.S. cannabis industry and that incremental revenues from new states slated to come online for adult use sales, coupled with a normalization in trend in legacy markets, as w
What happened Costco Wholesale (NASDAQ: COST) investors were in the red on Friday. The retailer's stock fell 2% by 3 p.m. ET compared with a 0.6% decline in the S&P 500. That drop pushed the stock down further in 2022, although shares are modestly outperforming the market's 13% loss so far this year.
ZIM (ZIM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Burned by Covid lockdowns and worker protests at Foxconn plants, the iPhone maker is looking to diversify the supply chain that has powered its growth.
PayPal Holdings, Inc (NASDAQ: PYPL) shares shed over 61% year-to-date. The shares have lost 5.5% in the last month and over 11% over the previous six months. On November 29, Deutsche Bank analyst Bryan Keane said Salesforce, Inc's (NYSE: CRM) new data shows Apple Inc (NASDAQ: AAPL) Pay growing at an "extremely rapid pace," up 52% Y/Y month-to-date in November globally and 59% Y/Y in the U.S. while, over the same period, PayPal adoption has fallen 8% globally and 4% in the U.S. Also Read: PayPal
After this year’s mauling, you can finally get a steady stream of retirement income from Treasury inflation-protected securities, or TIPS
Before you open a retirement account, you should know the disadvantages of Roth IRAs, including income limits. Learn about the drawbacks of Roth IRAs.
Let's see how AT&T (T), Verizon (VZ), and TMobile (TMUS) stocks compare and which may be the better buy at the moment.
What do Warren Buffett, Peter Lynch, and Seth Klarman all have in common? Not only are they widely viewed as some of the greatest investors of the modern era, they are all notable value investors. Value investing is an approach in which investors seek to buy stocks that they feel are underappreciated by the broader market.
Shares of Agenus (NASDAQ: AGEN) rose 12.5% on Friday. One big buyer was Values First Advisors, a financial advisory firm that bought 10,013 shares of the company and now owns 238,514 shares of Agenus. Agenus focuses on immuno-oncology therapies that boost the body's ability to fight cancer and infections by activating T-cell immune responses.
Question: I have heard it a thousand times: “People make more money with a financial advisor, don’t lock in your losses, stay invested,” etc. So I started with a financial adviser at a national firm in March. It has been a nearly continuous plunge of my savings, with a 13% loss in my portfolio, and yet not one adjustment has happened. If you have a portfolio that’s 50% stocks and 50% bonds, and you’re only down 13%, that means you’ve done fairly well, explains Joe Favorito, certified financial planner at Landmark Wealth Management.
Leave a Reply